[Current therapeutic options in Sjögren's syndrome].
Sjögren's syndrome is a systemic inflammatory-rheumatic disorder of hitherto unknown origin and, hence, adequate therapy options are not available in most cases. Treatment of sicca symptoms in Sjögren's patients is primarily symptomatic. Glucocorticoids, NSAIDs and/or immunosuppressive drugs may be used for the treatment of extraglandular manifestations or complications. Although there have been few clinical studies to date, new insights into the pathogenesis of this disorder may permit novel therapeutic strategies. Targeting B-cell candidates as a new therapeutic option in this entity has shown promising results. B-cell-depletion using Rituximab has been tested in initial clinical trials for the treatment of Sjögren patients, both with and without associated B-cell non-Hodgkin-lymphoma; however, further studies as well as reliable outcome criteria are needed. Further therapeutic options are currently in development or early clinical testing.
Hansen
A
A
Park-Klinik Weissensee, Akademisches Lehrkrankenhaus der Charité, Schönstr. 80, 13086 Berlin. hansen@park-klinik.com
Dörner
T
T
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes / Q000187:drug effects; D001688:Biological Products / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007638:Keratoconjunctivitis Sicca / Q000175:diagnosis / Q000188:drug therapy*; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000175:diagnosis / Q000188:drug therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001688:Biological Products; D005938:Glucocorticoids; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069283:Rituximab